Skip to main content
Loading…

Chamber and committees

Questions and answers

Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.

  • Written questions must be answered within 10 working days (20 working days during recess)
  • Other questions such as Topical, Portfolio, General and First Minister's Question Times are taken in the Chamber

Urgent Questions aren't included in the Question and Answers search.  There is a SPICe fact sheet listing Urgent and emergency questions.

Find out more about parliamentary questions

Filter your results Hide all filters

Dates of parliamentary sessions
  1. Session 1: 12 May 1999 to 31 March 2003
  2. Session 2: 7 May 2003 to 2 April 2007
  3. Session 3: 9 May 2007 to 22 March 2011
  4. Session 4: 11 May 2011 to 23 March 2016
  5. Session 5: 12 May 2016 to 4 May 2021
  6. Session 6: 13 May 2021 to 8 April 2026
  7. Current session: 14 May 2026 to 19 August 2026
Answer status
Question type

Displaying 186 questions Show Answers

Order by |

Question reference: S7W-02549

  • Asked by: Paul McLennan, MSP for East Lothian Coast and Lammermuirs, Scottish National Party
  • Date lodged: Tuesday, 18 August 2026
  • Current Status: Answer expected on 16 September 2026

To ask the Scottish Government what estimate it has made of the annual cost of providing semaglutide (Wegovy) and tirzepatide (Mounjaro) treatment for reducing weight in adults under the approved NHS Scotland Patient Access Scheme, and over what timescale it expects all eligible patients to be able to access treatment.

Question reference: S7W-02546

  • Asked by: Paul McLennan, MSP for East Lothian Coast and Lammermuirs, Scottish National Party
  • Date lodged: Tuesday, 18 August 2026
  • Current Status: Answer expected on 16 September 2026

To ask the Scottish Government, in light of NHS boards being expected to fund hybrid closed-loop (HCL) systems for eligible patients in line with NICE and SIGN guidance, what steps it will take to ensure equitable access to HCL across Scotland, and whether it will establish national targets and timelines for their continued roll-out.

Question reference: S7W-02544

  • Asked by: Paul McLennan, MSP for East Lothian Coast and Lammermuirs, Scottish National Party
  • Date lodged: Tuesday, 18 August 2026
  • Current Status: Answer expected on 16 September 2026

To ask the Scottish Government what information it holds on the number of people on waiting lists for hybrid closed-loop (HCL) insulin pumps and the number of planned new-start patients in 2026, broken down by NHS board.

Question reference: S7W-02548

  • Asked by: Paul McLennan, MSP for East Lothian Coast and Lammermuirs, Scottish National Party
  • Date lodged: Tuesday, 18 August 2026
  • Current Status: Answer expected on 16 September 2026

To ask the Scottish Government, in light of the Scottish Medicines Consortium's decision in June 2026 to approve the use of semaglutide (Wegovy) to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, what discussions it has had with NHS boards regarding implementation.

Question reference: S7W-02543

  • Asked by: Paul McLennan, MSP for East Lothian Coast and Lammermuirs, Scottish National Party
  • Date lodged: Tuesday, 18 August 2026
  • Current Status: Answer expected on 16 September 2026

To ask the Scottish Government how it plans to address any gaps in data in order to improve reporting against the National Indicators.

Question reference: S7W-02542

  • Asked by: Paul McLennan, MSP for East Lothian Coast and Lammermuirs, Scottish National Party
  • Date lodged: Tuesday, 18 August 2026
  • Current Status: Answer expected on 16 September 2026

To ask the Scottish Government whether it will provide details of its approach and timeline for the development of the National Indicators that underpin the National Outcomes, and how it plans to consult with relevant sectors and organisations as part of this process.

Question reference: S7W-02540

  • Asked by: Paul McLennan, MSP for East Lothian Coast and Lammermuirs, Scottish National Party
  • Date lodged: Tuesday, 18 August 2026
  • Current Status: Answer expected on 16 September 2026

To ask the Scottish Government what progress has been made in reviewing the National Performance Framework, including when the revised framework and National Outcomes will be published.

Question reference: S7W-02541

  • Asked by: Paul McLennan, MSP for East Lothian Coast and Lammermuirs, Scottish National Party
  • Date lodged: Tuesday, 18 August 2026
  • Current Status: Answer expected on 16 September 2026

To ask the Scottish Government whether the Programme for Government 2026-27 will be closely aligned or mapped to the revised National Performance Framework.

Question reference: S7W-02545

  • Asked by: Paul McLennan, MSP for East Lothian Coast and Lammermuirs, Scottish National Party
  • Date lodged: Tuesday, 18 August 2026
  • Current Status: Answer expected on 16 September 2026

To ask the Scottish Government whether it will consider routinely publishing national data on the number of people on waiting lists for hybrid closed-loop (HCL) insulin pumps and the number of new-start patients, to support transparency and identify any regional variation.

Question reference: S7W-02547

  • Asked by: Paul McLennan, MSP for East Lothian Coast and Lammermuirs, Scottish National Party
  • Date lodged: Tuesday, 18 August 2026
  • Current Status: Answer expected on 16 September 2026

To ask the Scottish Government how many new-start patients are planned to commence treatment with hybrid closed-loop (HCL) insulin pump systems in 2026, and how this compares with the number of new-start patients in 2024 and 2025.